Axillary Lymph Node Ultrasound Following Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: Results from the SN FNAC Study

2019 ◽  
Vol 26 (13) ◽  
pp. 4337-4345 ◽  
Author(s):  
Dominique Morency ◽  
Sinziana Dumitra ◽  
Elena Parvez ◽  
Karyne Martel ◽  
Mark Basik ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Neoadjuvant Chemotherapy ◽  
Axillary Lymph Node ◽  
Axillary Lymph ◽  
Node Positive ◽  
Lymph Node Ultrasound ◽  
Positive Breast Cancer

scholarly journals Axillary lymph node dissection in node-positive breast cancer: are ten nodes adequate and when is enough, enough?

2019 ◽  
Vol 179 (3) ◽  
pp. 661-670 ◽  
Author(s):  
Laura H. Rosenberger ◽  
Yi Ren ◽  
Samantha M. Thomas ◽  
Rachel A. Greenup ◽  
Oluwadamilola M. Fayanju ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Axillary Lymph Node Dissection ◽  
Lymph Node Dissection ◽  
Axillary Lymph Node ◽  
Axillary Lymph ◽  
Node Dissection ◽  
Node Positive ◽  
Positive Breast Cancer

The prognostic value of nodal ratios in node-positive breast cancer: AUBMC experience

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 21072-21072
Author(s):  
A. Shamseddine ◽  
H. Hatoum ◽  
Z. Salem ◽  
Z. Abdel Khalek ◽  
N. El Saghir ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Lymph Nodes ◽  
Axillary Lymph Node ◽  
Disease Free Survival ◽  
Axillary Lymph ◽  
Node Positive ◽  
The Impact ◽  
Positive Breast Cancer

21072 Background: Axillary lymph node metastasis has proven to be the most important factor affecting overall survival (OS) and disease free survival (DFS) in patients with breast cancer. Recent evidence suggests that axillary lymph node ratio (LNR) may be at least as important as absolute number of involved lymph nodes in predicting OS and DFS. The aim of this retrospective study is to evaluate the impact of axillary nodal ratios in node-positive breast cancer as a prognostic factor for survival. Methods: Data from 1181 patients with stage I, II and III breast cancer diagnosed at AUBMC between 1990 and 2001 were studied. The median age at diagnosis was 50 years (23 - 88); the median number of lymph nodes dissected was 17 (0 - 49). Survival was compared in 737 patients with node-positive disease according to a LNR below or more than 0.25 (defined as number of involved lymph nodes divided by total dissected axillary lymph nodes). Results: Patients with LNR = 0.25 had a median follow-up of 30 months (1.2–156) and a median DFS of 26 months (1–156). The 5-year survival was 26.2% (94/358) and the 5-year DFS was 22.9% (82/358). Patients with LNR <0.25 had a median follow-up of 36 months (1.2–157) and a median DFS of 36 months (1–157). The 5-year survival of 33.2% (245/737) and the 5-year DFS was 29.8 % (220/737). LNR showed significance as a continuous variable and a categorical variable (0, < 0.25, and = 0.25) with a p < 0.001 Conclusions: LNR significantly predicts OS and DFS in node-positive primary breast cancer. No significant financial relationships to disclose.

Is axillary lymph node clearance required in node-positive breast cancer?

2014 ◽  
Vol 12 (1) ◽  
pp. 55-61 ◽  
Author(s):  
Nigel J. Bundred ◽  
Nicola L. P. Barnes ◽  
Emiel Rutgers ◽  
Mila Donker
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Axillary Lymph Node ◽  
Axillary Lymph ◽  
Node Positive ◽  
Axillary Lymph Node Clearance ◽  
Positive Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document